Literature DB >> 17452776

655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations.

Stefania Tommasi1, Vita Fedele, Rosanna Lacalamita, Michele Bruno, Francesco Schittulli, David Ginzinger, Gery Scott, Serenella Eppenberger-Castori, Daniele Calistri, Silvia Casadei, Ian Seymour, Salvatore Longo, Gianluigi Giannelli, Brunella Pilato, Giovanni Simone, Christopher C Benz, Angelo Paradiso.   

Abstract

Human ERBB2 presents several SNPs. One of these, Ile655Val, introduces a structural change in the transmembrane region of ERBB2 and has been the focus of debate over its potential role as a susceptibility marker for breast cancer risk. Another SNP, Ala1170Pro, introduces a structural change in the carboxyl-terminal regulatory domain of the protein, but its clinical and biological importance remains undefined. The aim of this study was to investigate the association of rare alleles of both SNPs and the risk of developing breast cancer, BRCA1 alterations and clinical-pathological features of Caucasian breast cancer patients with familial history of breast/ovarian cancer. The originality of the present paper is that it is the only specifically focusing on the relationship between ERBB2 SNPs and familiarity/BRCA1 characteristics. A consecutive series of 628 patients with first diagnosis of breast cancer and 169 healthy people had DNA analyzed for both SNPs. Genotypic or allelic frequencies of ERBB2 SNPs in breast cancer patients were similar than in controls. The variant allele 655Val was significantly associated with younger age (p=0.009) particularly associated with patient family history of breast cancer (p=0.02). The 655Val allele was also more commonly found in invasive, while the variant 1170Pro in estrogen receptor positive breast cancers. Furthermore, this last SNP seems to be strictly associated with the presence of BRCA1 polymorphisms. In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17452776      PMCID: PMC4618199          DOI: 10.1155/2007/512518

Source DB:  PubMed          Journal:  Cell Oncol        ISSN: 1570-5870            Impact factor:   6.730


  7 in total

1.  HER2 Pro1170Ala polymorphism is associated with decreased survival rate in HER2-negative breast cancer.

Authors:  Pilei Si; Ye Xu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  Oncol Lett       Date:  2017-03-17       Impact factor: 2.967

2.  Genetic risk transmission in a family affected by familial breast cancer.

Authors:  Brunella Pilato; Simona De Summa; Katia Danza; Rosanna Lacalamita; Rossana Lambo; Domenico Sambiasi; Angelo Paradiso; Stefania Tommasi
Journal:  J Hum Genet       Date:  2013-10-24       Impact factor: 3.172

3.  HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.

Authors:  Oguz Ozturk; Emel Canbay; Ozlem T Kahraman; M Fatih Seyhan; Fatih Aydogan; Varol Celik; Cihan Uras
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

4.  HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

5.  "Sequencing-grade" screening for BRCA1 variants by oligo-arrays.

Authors:  Alessandro Monaco; Filippo Menolascina; Yingdong Zhao; Stefania Tommasi; Marianna Sabatino; Ross Fasano; Angelo Paradiso; Francesco M Marincola; Ena Wang
Journal:  J Transl Med       Date:  2008-10-30       Impact factor: 5.531

6.  The genetic polymorphisms of HER-2 and the risk of lung cancer in a Korean population.

Authors:  Uk Hyun Jo; Sle Gi Lo Han; Jae Hong Seo; Kyong Hwa Park; Jae Won Lee; Hyo Jung Lee; Jeong Seon Ryu; Yeul Hong Kim
Journal:  BMC Cancer       Date:  2008-12-04       Impact factor: 4.430

7.  Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.

Authors:  B Madhu Krishna; Sanjib Chaudhary; Aditya K Panda; Dipti Ranjan Mishra; Sandip K Mishra
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.